title: Bevacizumab for the treatment of recurrent glioblastoma.
abstract: Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab in managing GBM.
authors: Departments of Neurology and Neurological Surgery, University of Washington, Seattle, WA, USA.
authors: Marc C
authors: MC
authors: Chamberlain
references: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references: 17947719
references: J Clin Oncol. 2008 Dec 1;26(34):5649-50
references: 18981459
references: N Engl J Med. 2007 Dec 27;357(26):2666-76
references: 18160686
references: J Neurooncol. 2009 Feb;91(3):359-67
references: 18953491
references: Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7
references: 18513880
references: Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9
references: 18793954
references: Clin Cancer Res. 2008 Nov 1;14(21):7068-73
references: 18981004
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: Clin Cancer Res. 2007 Feb 15;13(4):1253-9
references: 17317837
references: Nature. 2006 Dec 7;444(7120):756-60
references: 17051156
references: J Clin Oncol. 1999 Aug;17(8):2572-8
references: 10561324
references: Neuro Oncol. 2008 Jun;10(3):355-60
references: 18436627
references: Cancer Res. 1999 Jul 15;59(14):3374-8
references: 10416597
references: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references: 19720927
references: Onkologie. 2004 Jun;27(3):261-6
references: 15249715
references: Oncology. 2005;69 Suppl 3:11-6
references: 16301831
references: Neuro Oncol. 2009 Oct;11(5):550-5
references: 19332770
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: Br J Cancer. 2003 Jul 7;89(1):8-14
references: 12838293
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Cancer. 2003 May 1;97(9 Suppl):2381-6
references: 12712460
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: Cancer Cell. 2004 Dec;6(6):553-63
references: 15607960
references: Neurosurgery. 1982 Apr;10(4):437-44
references: 7099393
references: CA Cancer J Clin. 2010 May-Jun;60(3):166-93
references: 20445000
references: Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7
references: 15380566
references: J Clin Oncol. 2007 Oct 20;25(30):4714-21
references: 17947718
references: Nat Rev Neurol. 2009 Nov;5(11):610-20
references: 19826401
references: Neurology. 1994 Apr;44(4):675-80
references: 8164824
references: Cancer. 2009 Apr 15;115(8):1734-43
references: 19197992
references: Expert Opin Biol Ther. 2008 Apr;8(4):541-53
references: 18352856
references: Neurology. 2011 Feb 1;76(5):432-7
references: 21282590
references: J Clin Oncol. 1999 May;17(5):1516-25
references: 10334539
references: J Clin Oncol. 2011 Jan 10;29(2):142-8
references: 21135282
references: Science. 2005 Jan 7;307(5706):58-62
references: 15637262
references: Neuro Oncol. 2005 Jul;7(3):246-53
references: 16053699
references: Cancer Cell. 2007 Jan;11(1):69-82
references: 17222791
references: Clin Cancer Res. 2008 May 1;14(9):2623-30
references: 18451225
references: Br J Cancer. 2009 Dec 15;101(12):1986-94
references: 19920819
references: Neuro Oncol. 2004 Jan;6(1):21-7
references: 14769136
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: J Neurooncol. 2007 Mar;82(1):81-3
references: 16944309
references: Neuro Oncol. 2007 Jan;9(1):29-38
references: 17108063
references: Neurology. 2009 Nov 17;73(20):1677-80
references: 19917990
references: J Neurooncol. 2002 Jan;56(2):183-8
references: 11995820
references: Neuro Oncol. 2006 Apr;8(2):189-93
references: 16533878
references: J Neurooncol. 2010 Jan;96(2):259-69
references: 19593660
references: Int J Cancer. 1999 Feb 19;84(1):10-8
references: 9988225
references: J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013
references: 18281677
references: Neuro Oncol. 2008 Apr;10(2):162-70
references: 18356283
references: Neurology. 2009 May 5;72(18):1601-6
references: 19414728
references: J Natl Cancer Inst. 1972 Feb;48(2):347-56
references: 4347034
references: Invest New Drugs. 2007 Jun;25(3):259-63
references: 17080256
references: J Clin Oncol. 2009 Feb 10;27(5):740-5
references: 19114704
references: Neuro Oncol. 2005 Apr;7(2):134-53
references: 15831232
references: Cancer Res. 2004 Jun 1;64(11):3731-6
references: 15172975
references: Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6
references: 17236958
references: Neurology. 2009 Apr 7;72(14):1217-22
references: 19349600
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: Nat Rev Neurosci. 2007 Aug;8(8):610-22
references: 17643088
references: Acta Neurochir (Wien). 2000;142(9):979-85
references: 11086806
references: J Clin Oncol. 1999 Sep;17(9):2762-71
references: 10561351
references: Neuro Oncol. 2011 Jan;13(1):143-51
references: 21084434
references: Neurology. 2008 Mar 4;70(10):779-87
references: 18316689
references: Clin Cancer Res. 2003 Aug 15;9(9):3369-75
references: 12960124
references: J Clin Oncol. 2008 Jan 10;26(2):271-8
references: 18182667
references: J Clin Oncol. 2000 Feb;18(4):708-15
references: 10673511
references: Cancer. 1996 Jan 15;77(2):362-72
references: 8625246
references: Neurology. 2006 Apr 25;66(8):1258-60
references: 16636248
references: J Neurooncol. 2009 Aug;94(1):63-8
references: 19189055
references: Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63
references: 19167838
references: Cancer. 2008 May 15;112(10):2267-73
references: 18327820
references: Oncologist. 2010;15(12):1329-34
references: 21147867
references: J Neurooncol. 2003 May;62(3):297-303
references: 12777082
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: J Neurosurg. 2007 Apr;106(4):601-8
references: 17432710
references: J Neurooncol. 2011 Jan;101(2):319-23
references: 21052776
references: Cancer Res. 2003 Jan 1;63(1):236-41
references: 12517803
references: J Neurooncol. 2011 Aug;104(1):287-91
references: 21153679
references: Clin Cancer Res. 2010 Apr 15;16(8):2443-9
references: 20371685
references: JAMA. 2005 Feb 2;293(5):557-64
references: 15687310